Page last updated: 2024-09-03

rb 6145 and Metastase

rb 6145 has been researched along with Metastase in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ali, M; Babur, M; Bloomer, WD; Cawthorne, C; Julyan, PJ; Lunt, SJ; Papadopoulou, MV; Price, PM; Smigova, A; Stratford, IJ; Telfer, BA; Williams, KJ1
Fitzmaurice, RJ; Lunt, SJ; Stratford, IJ; Telfer, BA; Williams, KJ1

Other Studies

2 other study(ies) available for rb 6145 and Metastase

ArticleYear
The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.
    British journal of cancer, 2010, Jul-13, Volume: 103, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation, Preclinical; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred C3H; Neoplasm Metastasis; Nitroimidazoles; Quinolines; Sarcoma; Tirapazamine; Triazines

2010
Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-01, Volume: 11, Issue:11

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Female; Hypoxia; Mice; Mice, Inbred C3H; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental; Tirapazamine; Treatment Outcome; Triazines

2005